Melanoma Brain Metastases Patient-Derived Organoids: An In Vitro Platform for Drug Screening

被引:0
|
作者
Abedellatif, Saif-Eldin [1 ]
Hosni, Racha [1 ]
Waha, Andreas [2 ]
Gielen, Gerrit H. [2 ]
Banat, Mohammed [3 ]
Hamed, Motaz [3 ]
Gueresir, Erdem [3 ]
Froehlich, Anne [4 ]
Sirokay, Judith [4 ]
Wulf, Anna-Lena [1 ]
Kristiansen, Glen [1 ]
Pietsch, Torsten [2 ]
Vatter, Hartmut [3 ]
Hoelzel, Michael [5 ]
Schneider, Matthias [3 ]
Toma, Marieta Ioana [1 ]
机构
[1] Univ Hosp Bonn, Inst Pathol, D-53127 Bonn, Germany
[2] Univ Hosp Bonn, Inst Neuropathol, D-53127 Bonn, Germany
[3] Univ Hosp Bonn, Dept Neurosurg, D-53127 Bonn, Germany
[4] Univ Hosp Bonn, Dept Dermatol, D-53127 Bonn, Germany
[5] Univ Hosp Bonn, Inst Expt Oncol, Bonn, Germany
关键词
melanoma; brain metastases; BRAF; organoids; DABRAFENIB;
D O I
10.3390/pharmaceutics16081042
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background and aims: Brain metastases are prevalent in the late stages of malignant melanoma. Multimodal therapy remains challenging. Patient-derived organoids (PDOs) represent a valuable pre-clinical model, faithfully recapitulating key aspects of the original tumor, including the heterogeneity and the mutational status. This study aimed to establish PDOs from melanoma brain metastases (MBM-PDOs) and to test the feasibility of using them as a model for in vitro targeted-therapy drug testing. Methods: Surgical resection samples from eight patients with melanoma brain metastases were used to establish MBM-PDOs. The samples were enzymatically dissociated followed by seeding into low-attachment plates to generate floating organoids. The MBM-PDOs were characterized genetically, histologically, and immunohistologically and compared with the parental tissue. The MBM-PDO cultures were exposed to dabrafenib (BRAF inhibitor) and trametinib (MEK inhibitor) followed by a cell viability assessment. Results: Seven out of eight cases were successfully cultivated, maintaining the histological, immunohistological phenotype, and the mutational status of the parental tumors. Five out of seven cases harbored BRAF V600E mutations and were responsive to BRAF and MEK inhibitors in vitro. Two out of seven cases were BRAF wild type: one case harboring an NRAS mutation and the other harboring a KIT mutation, and both were resistant to BRAF and MEK inhibitor therapy. Conclusions: We successfully established PDOs from melanoma brain metastases surgical specimens, which exhibited a consistent histological and mutational profile with the parental tissue. Using FDA-approved BRAF and MEK inhibitors, our data demonstrate the feasibility of employing MBM-PDOs for targeted-therapy in vitro testing.
引用
收藏
页数:13
相关论文
共 50 条
  • [31] Targeting mutant RAS in patient-derived colorectal cancer organoids by combinatorial drug screening
    Verissimo, Carla S.
    Overmeer, Rene M.
    Ponsioen, Bas
    Drost, Jarno
    Mertens, Sander
    Verlaan-Klink, Ingrid
    van Gerwen, Bastiaan
    van der Ven, Marieke
    van de Wetering, Marc
    Egan, David A.
    Bernards, Rene
    Clevers, Hans
    Bos, Johannes L.
    Snippert, Hugo J.
    eLife, 2016, 5
  • [32] The Role of Patient-Derived Organoids in Triple-Negative Breast Cancer Drug Screening
    Psilopatis, Iason
    Mantzari, Amalia
    Vrettou, Kleio
    Theocharis, Stamatios
    BIOMEDICINES, 2023, 11 (03)
  • [33] Acoustic Printing of Patient-Derived Organoids That Preserve Tumor Microenvironment for Personalized Drug Screening
    Gong, Zhiyi
    Mao, Yiqian
    Huang, Lanxiang
    Tang, Xuan
    Zhang, Lingling
    Xu, Yaqi
    Ding, Zhao
    Zhao, Xingzhong
    Wang, Fubing
    Guo, Shishang
    ADVANCED MATERIALS TECHNOLOGIES, 2023, 8 (11)
  • [34] Development of an Extracellular Matrix Plate for Drug Screening Using Patient-Derived Tumor Organoids
    Yong Hun Jung
    Kyungwon Park
    Minseop Kim
    Hyunjik Oh
    Dong-Hee Choi
    Jinchul Ahn
    Sat-byol Lee
    Kyuhwan Na
    Byung Soh Min
    Jin-A. Kim
    Seok Chung
    BioChip Journal, 2023, 17 : 284 - 292
  • [35] Author Correction: Establishment of patient-derived cancer organoids for drug-screening applications
    Else Driehuis
    Kai Kretzschmar
    Hans Clevers
    Nature Protocols, 2021, 16 : 5739 - 5739
  • [36] Patient-Derived Organoids Reveal Intrapatient Drug Response Heterogeneity in Pancreatic Neuroendocrine Liver Metastases
    Pu, Tracey
    Forsythe, Steven
    Desai, Priyanka
    Larrain, Carolina
    Victory, Jack
    Sarvestani, Amber Leila
    Lin, Yuri
    Akmal, Sarfraz R.
    Luberice, Kenneth
    Friedman, Lindsay
    Eade, Alyssa
    Rainey, Ashiq
    Stepp, Hannah
    Smith, Emily
    Romnert, Kirsten
    Sinha, Surajit
    Hannah, Cathleen
    Sadowski, Samira
    del Rivera, Jadira
    Hernandez, Jonathan M.
    ANNALS OF SURGICAL ONCOLOGY, 2024, 31 (01) : S158 - S158
  • [37] PATIENT-DERIVED ORGANOIDS FOR MODELING PEDIATRIC BRAIN TUMORS
    Lago, Chiara
    Ballabio, Claudio
    Miele, Evelina
    Tiberi, Luca
    NEURO-ONCOLOGY, 2022, 24 : 171 - 171
  • [38] Development of automated 3D high-throughput drug screening platform for patient-derived breast cancer organoids
    Kim, Jungeun
    Kim, Hoe Suk
    Kim, Ga Yeon
    Park, Kyung Hyeun
    Ryu, Seung Yeon
    Lee, Sangeun
    Lee, Dong Woo
    Ku, Bosung
    Lee, Han-Byoel
    Han, Wonshik
    CANCER RESEARCH, 2022, 82 (04)
  • [39] Establishment of patient-derived organoids and a characterization based drug discovery platform for treatment of gastric cancer
    Chen, Guo
    Han, Ruidong
    Wang, Li
    Ma, Wen
    Zhang, Wenli
    Lu, Zifan
    Wang, Lei
    CANCER CELL INTERNATIONAL, 2024, 24 (01)
  • [40] Real-time drug testing using patient-derived organoids from resected breast cancer brain metastases.
    Morikawa, Aki
    Merrill, Nathan
    Bao, Liwei
    Cheng, Xu
    Freedman, Ruth
    Verbal, Kait
    Heth, Jason
    Soellner, Matthew
    Merajver, Sofia
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)